Faculty Opinions recommendation of Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Author(s):  
Scott Halstead
2012 ◽  
Vol 86 (7) ◽  
pp. 4019-4023 ◽  
Author(s):  
W. M. P. B. Wahala ◽  
C. Huang ◽  
S. Butrapet ◽  
L. J. White ◽  
A. M. de Silva

2007 ◽  
Vol 81 (23) ◽  
pp. 12816-12826 ◽  
Author(s):  
Soila Sukupolvi-Petty ◽  
S. Kyle Austin ◽  
Whitney E. Purtha ◽  
Theodore Oliphant ◽  
Grant E. Nybakken ◽  
...  

ABSTRACT Neutralization of flaviviruses in vivo correlates with the development of an antibody response against the viral envelope (E) protein. Previous studies demonstrated that monoclonal antibodies (MAbs) against an epitope on the lateral ridge of domain III (DIII) of the West Nile virus (WNV) E protein strongly protect against infection in animals. Based on X-ray crystallography and sequence analysis, an analogous type-specific neutralizing epitope for individual serotypes of the related flavivirus dengue virus (DENV) was hypothesized. Using yeast surface display of DIII variants, we defined contact residues of a panel of type-specific, subcomplex-specific, and cross-reactive MAbs that recognize DIII of DENV type 2 (DENV-2) and have different neutralizing potentials. Type-specific MAbs with neutralizing activity against DENV-2 localized to a sequence-unique epitope on the lateral ridge of DIII, centered at the FG loop near residues E383 and P384, analogous in position to that observed with WNV-specific strongly neutralizing MAbs. Subcomplex-specific MAbs that bound some but not all DENV serotypes and neutralized DENV-2 infection recognized an adjacent epitope centered on the connecting A strand of DIII at residues K305, K307, and K310. In contrast, several MAbs that had poor neutralizing activity against DENV-2 and cross-reacted with all DENV serotypes and other flaviviruses recognized an epitope with residues in the AB loop of DIII, a conserved region that is predicted to have limited accessibility on the mature virion. Overall, our experiments define adjacent and structurally distinct epitopes on DIII of DENV-2 which elicit type-specific, subcomplex-specific, and cross-reactive antibodies with different neutralizing potentials.


2008 ◽  
Vol 82 (12) ◽  
pp. 6024-6033 ◽  
Author(s):  
Eva Lee ◽  
Mario Lobigs

ABSTRACT The yellow fever virus (YFV) 17D strain is one of the most effective live vaccines for human use, but the in vivo mechanisms for virulence attenuation of the vaccine and the corresponding molecular determinants remain elusive. The vaccine differs phenotypically from wild-type YFV by the loss of viscerotropism, despite replicative fitness in cell culture, and genetically by 20 amino acid changes predominantly located in the envelope (E) protein. We show that three residues in E protein domain III inhibit spread of 17D in extraneural tissues and attenuate virulence in type I/II interferon-deficient mice. One of these residues (Arg380) is a dominant glycosaminoglycan-binding determinant, which mainly accounts for more rapid in vivo clearance of 17D from the bloodstream in comparison to 17D-derived variants with wild-type-like E protein. While other mutations will account for loss of neurotropism and phenotypic stability, the described impact of E protein domain III changes on virus dissemination and virulence is the first rational explanation for the safety of the 17D vaccine in humans.


2015 ◽  
Vol 9 (7) ◽  
pp. e0003947 ◽  
Author(s):  
Monica Poggianella ◽  
José L. Slon Campos ◽  
Kuan Rong Chan ◽  
Hwee Cheng Tan ◽  
Marco Bestagno ◽  
...  

2014 ◽  
Vol 453 (3) ◽  
pp. 309-315 ◽  
Author(s):  
Sai Hari A. Gandham ◽  
David E. Volk ◽  
Ganesh L.R. Lokesh ◽  
Muniasamy Neerathilingam ◽  
David G. Gorenstein

Sign in / Sign up

Export Citation Format

Share Document